Drugs / SIM1811-03
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05569057 | Sep 2022 → Jun 2024 | primary cutaneous T-cell lymphoma | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05781386 | Mar 2022 → Jun 2025 | primary cutaneous T-cell lymphoma | Jiangsu Simcere Biologics Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIM1811-03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05781386 ↗ |
| Modality | Monoclonal antibody | “SIM1811-03 is a first-in-class IgG1-based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors.” NCT05569057 ↗ |
| Route | Intravenous | “Eligible subjects will receive intravenous infusion of SIM1811-03 on Days 1 and 15 of each 28-day cycle.” NCT05569057 ↗ |